0000000000954522

AUTHOR

Gerrit Toenges

showing 24 related works from this author

Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy

2019

Diagnosis of covert hepatic encephalopathy (CHE) is time consuming in clinical practice. Recently, a new diagnostic tool - the simplified Animal Naming Test (S-ANT1) - was presented with promising results in an Italian cohort. The aim of the present study was to validate S-ANT1 in a cohort of cirrhotic patients from a German tertiary referral centre.143 cirrhotic patients and 37 healthy controls were enrolled. Hepatic encephalopathy (HE) grade 1 (HE1) was clinically diagnosed according to the West-Haven Criteria. Critical flicker frequency and Psychometric Hepatic Encephalopathy Score were used to detect minimal HE (MHE). All participants were additionally examined by S-ANT1.58 (40.6%) pati…

Liver CirrhosisMalePediatricsmedicine.medical_specialtyPsychometricsFlicker fusion thresholdNeuropsychological Tests030204 cardiovascular system & hematologyRisk AssessmentSeverity of Illness Index03 medical and health sciences0302 clinical medicineReference ValuesGermanyInternal MedicinemedicineAnimalsHumansIn patientProspective Studies030212 general & internal medicineHepatic encephalopathyAgedbusiness.industryMiddle Agedmedicine.diseaseTest (assessment)Clinical PracticeROC CurveCovertCase-Control StudiesHepatic EncephalopathyCohortFemalebusinessPrimary screeningEuropean Journal of Internal Medicine
researchProduct

Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation.

2019

Background & Aims: Fibrosis progression (FP) after liver transplantation (LT) increases morbidity and mortality. Biomarkers are needed for early prediction of FP. A recipient’s seven-gene cirrhosis risk score (CRS) has been associated with FP, especially in non-transplant cohorts. A broader validation of CRS, including the genotype of the donor-organ and HCV-negative patients is lacking. We therefore analyzed the impact of donor- and recipient-specific genotypes on FP after LT in a large cohort of HCV-positive and -negative patients.Method: Genotyping from liver biopsies (n=201 donors) and peripheral blood (n=442 recipients) was performed. Cirrhosis risk score was correlated with FP at …

0301 basic medicineGenetic MarkersLiver CirrhosisMalemedicine.medical_specialtyCirrhosisTime Factorsmedicine.medical_treatmentLiver transplantationGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisRisk FactorsInternal medicineGenotypeotorhinolaryngologic diseasesMedicineHumansCumulative incidenceGenetic Predisposition to DiseaseFramingham Risk Scorebusiness.industryHazard ratioGastroenterologyMiddle Agedmedicine.diseaseTissue DonorsLiver Transplantation030104 developmental biologyPhenotypeTreatment OutcomeDisease Progression030211 gastroenterology & hepatologyFemalebusinessRisk assessmentJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis

2020

Non-selective β-blockers (NSBB) are frequently used for the treatment of portal hypertension and gastroesophageal varices in patients with liver cirrhosis; however prospective studies investigating the potential association between NSBB use and hepatic encephalopathy (HE) are still scarce. We investigated the potential association between NSBB use and the presence of covert HE (CHE) as well as the development of overt HE (OHE).224 patients with liver cirrhosis were included into this cohort study at two German centers and followed for a median of 364 days. CHE was diagnosed by pathological results in the PHES. Predictors for the presence of CHE or the development of OHE were analyzed using …

Liver Cirrhosismedicine.medical_specialtyCirrhosis030204 cardiovascular system & hematologyLogistic regressionGastroenterologyCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineHypertension PortalInternal MedicinemedicineHumansCumulative incidenceProspective Studies030212 general & internal medicineProspective cohort studyPathologicalHepatic encephalopathyintegumentary systembusiness.industrymedicine.diseaseHepatic EncephalopathyPortal hypertensionbusinessCohort studyEuropean Journal of Internal Medicine
researchProduct

Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy

2019

BACKGROUND Systemic inflammation is a driving force for the development of hepatic encephalopathy and recent studies demonstrated that elevated Interleukin-6 (IL-6) serum levels are associated with the presence of minimal hepatic encephalopathy in patients with liver cirrhosis. AIM To test the hypothesis that IL-6 is a suitable marker to identify patients with liver cirrhosis at high risk for the development of overt hepatic encephalopathy. METHODS 201 patients were included into this prospective cohort study and were followed for a mean time of 322 days. Covert hepatic encephalopathy was diagnosed according to the West-Haven criteria (hepatic encephalopathy grade 1) and with the portosyste…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSystemic inflammationSensitivity and SpecificityGastroenterologyDiagnosis Differential03 medical and health sciencesLiver disease0302 clinical medicineRisk FactorsInternal medicineHumansMedicinePharmacology (medical)Cumulative incidenceProspective Studies030212 general & internal medicineInterleukin 6Prospective cohort studyPortosystemic encephalopathyHepatic encephalopathyAgedInflammationHepatologybiologyInterleukin-6business.industryGastroenterologyMiddle Agedmedicine.diseaseUp-RegulationC-Reactive ProteinHepatic Encephalopathybiology.proteinFemale030211 gastroenterology & hepatologymedicine.symptombusinessBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct

Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis

2020

Background Diabetes mellitus may lead to increased serum ammonia and systemic inflammation thereby promoting hepatic encephalopathy (HE). Aim To investigate the potential association between diabetes mellitus/glycaemic control and the presence of covert HE as well as the development of overt HE in a prospective setting. Methods A total of 240 patients with liver cirrhosis were included into this prospective cohort study and followed for a median of 17 months. Covert HE was diagnosed by pathological results in the Portosystemic Hepatic Encephalopathy Score. Predictors for the presence of covert HE or the development of overt HE were analysed using logistic regression or Cox-regression models…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryGastroenterologymedicine.diseaseLogistic regressionGastroenterologyInternal medicineDiabetes mellitusmedicinePharmacology (medical)Liver functionProspective cohort studybusinessComplicationPathologicalHepatic encephalopathyAlimentary Pharmacology & Therapeutics
researchProduct

Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population

2021

Background: This study sought to investigate the prevalence and clinical outcome of left ventricular (LV) geometry in prediabetes and type 2 diabetes mellitus (T2DM) and the impact of glucose metabolism on the incidence of left ventricular hypertrophy (LVH). Methods: 15,010 subjects (35–74 years) of the population-based Gutenberg Health Study were categorized into euglycemia, prediabetes, and T2DM according to clinical and metabolic (HbA1c) information. Clinical outcome was assessed via structured follow-up. Results: The study comprised 12,121 individuals with euglycemia (81.6%), 1415 with prediabetes (9.5%), and 1316 with T2DM (8.9%). Prevalence of LVH increased from euglycemia (10.2%) ove…

medicine.medical_specialtyendocrine system diseasestype 2 diabetes mellitusPopulationprediabetesCarbohydrate metabolismleft ventricular concentric remodelingLeft ventricular hypertrophyArticleInternal medicineMedicineMass indexPrediabetescardiovascular diseaseseducationeducation.field_of_studybusiness.industryIncidence (epidemiology)Hazard ratioRType 2 Diabetes Mellitusnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseleft ventricular hypertrophyleft ventricular geometryCardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct

Impact of cardiopulmonary resuscitation on a cannot intubate, cannot oxygenate condition: a randomised crossover simulation research study of the int…

2019

ObjectivesDuring a ‘cannot intubate, cannot oxygenate’ situation, asphyxia can lead to cardiac arrest. In this stressful situation, two complex algorithms facilitate decision-making to save a patient’s life: difficult airway management and cardiopulmonary resuscitation. However, the extent to which competition between the two algorithms causes conflicts in the execution of pivotal treatment remains unknown. Due to the rare incidence of this situation and the very low feasibility of such an evaluation in clinical reality, we decided to perform a randomised crossover simulation research study. We propose that even experienced healthcare providers delay cricothyrotomy, a lifesaving approach, d…

AdultMale1682medicine.medical_treatmentCrossoverClinical Decision-MakingCardiopulmonary Resuscitation [E02.365.647.110]Simulated patientAnaesthesia03 medical and health sciences0302 clinical medicineManikins [J01.897.280.500.545.129.400]medicineHumansCricothyrotomy030212 general & internal medicineCardiopulmonary resuscitation1506Airway ManagementOriginal ResearchAsphyxiaCross-Over Studiesbusiness.industryAirway Management [E02.041]Patient SelectionGeneral MedicineUniversity hospitalCrossover studyCardiopulmonary ResuscitationAnesthesiology [H02.403.066]Heart ArrestHigh Fidelity Simulation Training[MeSH Tree numbers]: SimulationFemalemedicine.symptomLaryngeal MusclesbusinessAlgorithmHealthcare providers030217 neurology & neurosurgeryAlgorithmsBMJ Open
researchProduct

Marginal hazard ratio estimates in joint frailty models for heart failure trials

2019

Abstract This work is motivated by clinical trials in chronic heart failure disease, where treatment has effects both on morbidity (assessed as recurrent non‐fatal hospitalisations) and on mortality (assessed as cardiovascular death, CV death). Recently, a joint frailty proportional hazards model has been proposed for these kind of efficacy outcomes to account for a potential association between the risk rates for hospital admissions and CV death. However, more often clinical trial results are presented by treatment effect estimates that have been derived from marginal proportional hazards models, that is, a Cox model for mortality and an Andersen–Gill model for recurrent hospitalisations. …

Statistics and ProbabilityBiometryleast false parameterDiseasejoint frailty modelRisk AssessmentStudy durationCardiovascular deathunexplained heterogeneitymedicineHumansTreatment effectComplex Regression ModelsProportional Hazards ModelsHeart FailureClinical Trials as TopicProportional hazards modelbusiness.industryheart failure trialsHazard ratioGeneral Medicinemedicine.diseaseClinical trialrecurrent eventsHeart failureAsymptomatic DiseasesStatistics Probability and UncertaintybusinessDemographyResearch PaperBiometrical Journal. Biometrische Zeitschrift
researchProduct

Health-related quality of life in patients with compensated and decompensated liver cirrhosis.

2019

Compensated (Child-Pugh [CP] A) and decompensated (CP B/C) liver cirrhosis significantly differs in terms of impairment of health-related quality of life (HRQoL). However, sufficient data on potentially treatable factors associated with HRQoL in both stages of the disease are still lacking. Consequently, aims of this study were to determine differences in HRQoL between patients with compensated and decompensated liver cirrhosis and to identify potentially treatable factors associated with HRQoL.218 patients with liver cirrhosis were enrolled into this study. Chronic Liver Disease Questionnaire (CLDQ) was used to assess HRQoL. Covert hepatic encephalopathy (CHE) was diagnosed according to a …

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsDisease030204 cardiovascular system & hematologyChronic liver diseaseGastroenterologySeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of lifeRisk FactorsInternal medicineGermanySurveys and QuestionnairesInternal MedicinemedicineHumansRoutine clinical practiceIn patient030212 general & internal medicineProspective StudiesHepatic encephalopathyAgedHealth related quality of lifebusiness.industryMiddle Agedmedicine.diseasehumanitiesHepatic EncephalopathyMultivariate AnalysisLinear ModelsQuality of LifeFemalebusinessEuropean journal of internal medicine
researchProduct

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis

2019

Background: The course of multiple sclerosis (MS) shows substantial inter-individual variability. The underlying determinants of disease severity likely involve genetic and environmental factors. Objective: The aim of this study was to assess the impact of APOE and HLA polymorphisms as well as smoking and body mass index (BMI) in the very early MS course. Methods: Untreated patients ( n = 263) with a recent diagnosis of relapsing-remitting (RR) MS or clinically isolated syndrome underwent standardized magnetic resonance imaging (MRI). Genotyping was performed for single-nucleotide polymorphisms (SNPs) rs3135388 tagging the HLA-DRB1*15:01 haplotype and rs7412 (Ɛ2) and rs429358 (Ɛ4) in APOE. …

AdultMaleApolipoprotein EMultiple SclerosisAdolescentPolymorphism Single NucleotideBody Mass IndexYoung Adult03 medical and health sciencesApolipoproteins E0302 clinical medicineAtrophyMedizinische FakultätmedicineHumansSNPGenetic Predisposition to Disease030212 general & internal medicineddc:610Risk factorHLA-DRB1Agedbusiness.industryMultiple sclerosisSmokingNeurodegenerationBrainMiddle Agedmedicine.diseaseNeurologyImmunologyFemaleNeurology (clinical)AtrophybusinessBody mass index030217 neurology & neurosurgeryHLA-DRB1 Chains
researchProduct

Liver injury in patients with severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis.

2020

OBJECTIVE: Coronavirus disease-19 (COVID-19) infection is a global health threat. To inform the liver community on the potential relevance of COVID-19, we performed a systematic review and meta-analysis of published data on liver injury in patients with COVID-19 infection. METHODS: We searched PubMed and Google Scholar through 22 March according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Pooled data were analyzed by using random-effects meta-analyses. RESULTS: A total of 14 studies combining data from 2.871 patients were identified. The prevalence of pre-existing liver disease was reported at 3.1%. The pooled prevalence of elevated aspartate aminot…

medicine.medical_specialtyGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineLiver Function TestsInternal medicinemedicineHumansClinical significanceAspartate AminotransferasesProspective cohort studyLiver injurybiologymedicine.diagnostic_testHepatologybusiness.industrySARS-CoV-2Liver DiseasesGastroenterologyCOVID-19Alanine Transaminasemedicine.diseaseConfidence intervalAlanine transaminaseLiver030220 oncology & carcinogenesisMeta-analysisbiology.protein030211 gastroenterology & hepatologyLiver function testsbusinessEuropean journal of gastroenterologyhepatology
researchProduct

Computational issues in fitting joint frailty models for recurrent events with an associated terminal event.

2020

Abstract Background and objective: Joint frailty regression models are intended for the analysis of recurrent event times in the presence of informative drop-outs. They have been proposed for clinical trials to estimate the effect of some treatment on the rate of recurrent heart failure hospitalisations in the presence of drop-outs due to cardiovascular death. Whereas a R-software-package for fitting joint frailty models is available, some technical issues have to be solved in order to use SASⓇ 1 software, which is required in the regulatory environment of clinical trials. Methods: First, we demonstrate how to solve these issues by deriving proper likelihood-decompositions, in particular fo…

Computer scienceHealth InformaticsMachine learningcomputer.software_genre030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineLinear regressionHumansComputer SimulationEvent (probability theory)ProbabilityProportional Hazards ModelsHeart FailureLikelihood FunctionsFrailtybusiness.industryModels CardiovascularReproducibility of ResultsRegression analysisConfidence intervalComputer Science ApplicationsHospitalizationTransformation (function)Data Interpretation StatisticalMultivariate AnalysisArtificial intelligencebusinesscomputer030217 neurology & neurosurgeryAlgorithmsSoftwareComputer methods and programs in biomedicine
researchProduct

A comparison of semiparametric approaches to evaluate composite endpoints in heart failure trials

2021

In heart failure trials efficacy is usually proven by a composite endpoint including cardiovascular death (CVD) and recurrent heart failure hospitalisations (HFH), evaluated with time-to-first-event analysis based on a Cox model. As a considerable fraction of events is ignored that way, recurrent event[for full text, please go to the a.m. URL]

Statistics and Probabilitymedicine.medical_specialtyEpidemiology610 Medizinheart failureleast false parameterPositive correlationjoint frailty modelCorrelationLWYY model610 Medical sciencesInternal medicineMulticenter trialmedicineHumansTreatment effectFraction (mathematics)proportional rates modelsProportional Hazards ModelsProportional hazards modelbusiness.industry610 Medical sciences; Medicinemedicine.diseasecomposite endpointRecurrent eventTreatment Outcomeddc: 610recurrent eventsHeart failureCardiologybusiness
researchProduct

Abstract WP200: Development and Validation of a Score to Detect Paroxysmal Atrial Fibrillation During Long-term Holter-monitoring After Acute Ischemi…

2018

Introduction: Atrial fibrillation remains one of the most common causes of ischemic stroke. The diagnosis of paroxysmal atrial fibrillation (pAF) frequently escapes routine diagnostic due to its intermittent and asymptomatic occurrence. Currently prolonged monitoring times (72h) are recommended, but did not find their way into everyday practice. Therefore an individual patient selection for prolonged ECG-monitoring might increase the diagnostic yield of pAF in a resource-saving and cost-effective manner. Methods: We used individual patient data from three prospective studies (n total =1556) which performed a prolonged Holter ECG-monitoring (at least 72 h) and centralized data evaluation af…

Advanced and Specialized Nursingmedicine.medical_specialtymedicine.diagnostic_testbusiness.industryParoxysmal atrial fibrillationAtrial fibrillation030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineInternal medicineIschemic strokeCardiologymedicineNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessHolter monitoringStrokeElectrocardiographyAcute ischemic stroke030217 neurology & neurosurgeryStroke
researchProduct

Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis.

2019

Diagnosis of covert hepatic encephalopathy (CHE) is challenging and often neglected in clinical practice. The aim of this study was to develop an easy-to-perform score to predict CHE in patients with cirrhosis.For the development or validation cohort of the proposed clinical CHE score, 142 or 96 consecutive patients with cirrhosis were prospectively enrolled. The Psychometric Hepatic Encephalopathy Score was used to detect minimal hepatic encephalopathy. All patients were examined with the simplified animal naming test and were asked to complete the Chronic Liver Disease Questionnaire. We followed the TRIPOD guideline for development, validation, and reporting of the proposed score.The clin…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisgenetic structuresPsychometricsRisk AssessmentPrognostic score03 medical and health sciences0302 clinical medicineQuality of lifePredictive Value of TestsInternal medicinemedicineHumansIn patientHepatic encephalopathyintegumentary systemHepatologybusiness.industryGastroenterologyReproducibility of ResultsMiddle Agedmedicine.diseasePrognosisClinical PracticeEarly DiagnosisCovert030220 oncology & carcinogenesisPredictive value of testsHepatic EncephalopathyQuality of Life030211 gastroenterology & hepatologyFemalebusinessThe American journal of gastroenterology
researchProduct

Entwicklung und Validierung des NAFLD Cirrhosis Score (NCS) zur Separierung von fortgeschrittener Fibrose und Zirrhose

2021

Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV)
researchProduct

Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2) : a multinational, multicentre, single-ar…

2021

BACKGROUND: Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. METHODS: We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. …

Malemedicine.medical_specialtyPopulationAdministration OralHemorrhage030204 cardiovascular system & hematologyDrug Administration ScheduleDabigatran03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumans030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_studyRIGHT-VENTRICULAR DYSFUNCTION VENOUS THROMBOEMBOLISM DABIGATRAN MANAGEMENT WARFARIN HOSPITALIZATION RATIONALE HEPARIN DESIGNHeparinbusiness.industryAnticoagulantsVenous ThromboembolismHematologyGuidelineHeparinMiddle AgedInterim analysismedicine.diseaseThrombosisDabigatran3. Good healthPulmonary embolismClinical trialTreatment OutcomeFemalePulmonary EmbolismbusinessFollow-Up Studiesmedicine.drug
researchProduct

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

2020

INTRODUCTION: Despite the negative impact of covert hepatic encephalopathy on the outcome of patients with liver cirrhosis, data regarding the ability of different testing strategies to predict overt hepatic encephalopathy (OHE) development and mortality are limited. This study aimed to compare the ability of Psychometric Hepatic Encephalopathy Score (PHES), critical flicker frequency (CFF), simplified animal naming test (S-ANT1), and clinical covert hepatic encephalopathy (CCHE) score to predict OHE development and mortality. METHODS: A total of 224 patients with liver cirrhosis were tested with different testing strategies and prospectively followed up regarding clinically relevant outcom…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationRisk AssessmentSeverity of Illness IndexArticleEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicinePredictive Value of TestsInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyHepatic encephalopathyAgedReceiver operating characteristicbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsHepatic EncephalopathyFeasibility Studies030211 gastroenterology & hepatologyFemalebusinessFollow-Up StudiesClinical and Translational Gastroenterology
researchProduct

Clinical Frailty Scale for Risk Stratification in Patients with Sars-Cov-2 Infection

2020

Predictive factors for adverse outcomes in patients with COVID-19 are urgently needed. Data related to the applicability of the Clinical Frailty Scale (CFS) for risk stratification in patients with COVID-19 are currently lacking. We investigated the ability of CFS to predict need for mechanical ventilation and the duration of hospital stays in European patients with COVID-19. In total, 42 patients with confirmed COVID-19 infection admitted to the University Medical Center Mainz between March 3 and April 15 2020 were included into this validation study and data were retrospectively analyzed. CFS was assessed at admission in all patients. Patients were followed for need for mechanical ventil…

Male2474medicine.medical_specialtyTime FactorsMultivariate analysisintensive care unitsmedicine.medical_treatmentPneumonia ViralRisk AssessmentSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyBetacoronavirusGermanyInternal medicineSeverity of illnessHumansMedicineIn patientPandemicsAgedRetrospective StudiesMechanical ventilationRespiratory Distress SyndromeFrailtySARS-CoV-2business.industryProportional hazards modelBrief ReportAge FactorsCOVID-19Retrospective cohort studyGeneral MedicineLength of StayMiddle AgedRespiration ArtificialPatient DischargeMultivariate AnalysisRisk stratificationFemaleCoronavirus InfectionsRisk assessmentbusinessJournal of Investigative Medicine
researchProduct

Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy.

2018

Background Current EASL/AASLD guidelines recommend treatment of covert hepatic encephalopathy (HE) only in symptomatic patients, for example, in those with impaired quality of life or with affected driving abilities. Goals Because testing for impaired quality of life is time consuming, the aim of the present study was to identify simple clinical predictors for poor quality of life in patients with covert HE (CHE). Study In total, 139 cirrhotic in- and outpatients without a history of overt hepatic encephalopathy were enrolled. Diagnosis of HE grade 1 (HE1) was diagnosed clinically according to the West-Haven Criteria. Critical flicker frequency and the Psychometric Hepatic Encephalopathy Sc…

AdultLiver CirrhosisMalemedicine.medical_specialtyMultivariate analysisPsychometricsMEDLINEFlicker fusion thresholdChronic liver diseaseSex FactorsQuality of lifeInternal medicineSurveys and QuestionnairesmedicineHumansIn patientProspective StudiesHepatic encephalopathyAgedAged 80 and overbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisCovertHepatic EncephalopathyPractice Guidelines as TopicQuality of LifeAccidental FallsFemalebusinessJournal of clinical gastroenterology
researchProduct

Sarcopenia as prognostic factor for survival after orthotopic liver transplantation

2020

Background and aim Body composition has emerged as a prognostic factor for end-stage liver disease. We therefore investigated muscle mass, body fat and other clinical-pathological variables as predictors of posttransplant survival. Methods A total of 368 patients, who underwent orthotopic liver transplantation (OLT) at our institution, were assessed prior to OLT and followed for a median of 9.0 years (range 2.0-10.0 years) after OLT. Psoas, erector spinae and the combined paraspinal muscle area, as well as the corresponding indices normalized by body-height squared, were quantified by a lumbar (L3) cross-sectional computed tomography. In addition, absolute body fat and bone density were est…

AdultMaleSarcopeniamedicine.medical_specialtyBone densityUrologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineLumbarErector spinae musclesHumansMedicineRetrospective StudiesAnatomy Cross-SectionalHepatologybusiness.industryHazard ratioGastroenterologyHepatitis CMiddle AgedPrognosismedicine.diseaseConfidence intervalLiver Transplantation030220 oncology & carcinogenesisSarcopeniaBody CompositionFemale030211 gastroenterology & hepatologyTomography X-Ray ComputedbusinessEuropean Journal of Gastroenterology & Hepatology
researchProduct

Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients

2018

BACKGROUND Minimal hepatic encephalopathy (HE) and HE grade 1 (HE1) according to the West Haven criteria have recently been grouped as one entity named-covert HE- (CHE). Data regarding the impact of CHE on health-related quality of life (HRQoL) and sleep quality are controversial. AIM First, to determine whether CHE affects HRQoL and sleep quality of cirrhotic patients and second, whether minimal HE (MHE) and HE1 affect HRQoL and sleep quality to a comparable extent. METHODS A total of 145 consecutive cirrhotic patients were enrolled. HE1 was diagnosed clinically according to the West Haven criteria. Critical flicker frequency and the Psychometric Hepatic Encephalopathy Score were used to d…

medicine.medical_specialtyMultivariate analysisHepatologyPsychometricsbusiness.industryGastroenterologyChronic liver diseasemedicine.diseasehumanitiesPittsburgh Sleep Quality Index03 medical and health sciences0302 clinical medicineQuality of life030220 oncology & carcinogenesisInternal medicineMedicine030211 gastroenterology & hepatologyPharmacology (medical)businessProspective cohort studyHepatic encephalopathyCohort studyAlimentary Pharmacology & Therapeutics
researchProduct

Is APOE ε4 associated with cognitive performance in early MS?

2020

ObjectiveTo assess the impact of APOE polymorphisms on cognitive performance in patients newly diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS).MethodsThis multicenter cohort study included 552 untreated patients recently diagnosed with CIS or RRMS according to the 2005 revised McDonald criteria. The single nucleotide polymorphisms rs429358 (ε4) and rs7412 (ε2) of the APOE haplotype were assessed by allelic discrimination assays. Cognitive performance was evaluated using the 3-second paced auditory serial addition test and the Multiple Sclerosis Inventory Cognition (MUSIC). Sum scores were calculated to approximate the overall cognitive performance and memo…

OncologyApolipoprotein Emedicine.medical_specialtyClinically isolated syndromemedicine.diagnostic_testPaced Auditory Serial Addition Testbusiness.industryMultiple sclerosisCognitionMcDonald criteria610 Medicine & healthmedicine.diseaseNeurologyInternal medicinemedicineddc:610Neurology (clinical)Effects of sleep deprivation on cognitive performance610 Medicine & healthFunction and Dysfunction of the Nervous SystembusinessCohort study
researchProduct

MSJ763541_supplementary_material – Supplemental material for Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atroph…

2018

Supplemental material, MSJ763541_supplementary_material for Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis by Christiane Graetz, Adriane Gröge, Felix Luessi, Anke Salmen, Daniela Zöller, Janine Schultz, Nelly Siller, Vinzenz Fleischer, Barbara Bellenberg, Achim Berthele, Viola Biberacher, Joachim Havla, Michael Hecker, Reinhard Hohlfeld, Carmen Infante-Duarte, Jan S Kirschke, Tania Kümpfel, Ralf Linker, Friedemann Paul, Steffen Pfeuffer, Philipp Sämann, Gerrit Toenges, Frank Weber, Uwe K Zettl, Antje Jahn-Eimermacher, Gisela Antony, Sergiu Groppa, Heinz Wiendl, Bernhard Hemmer, Mark Mühlau, Carsten Lukas, Ralf Gold, Chri…

FOS: Clinical medicine111702 Aged Health CareFOS: Health sciences110904 Neurology and Neuromuscular Diseases
researchProduct